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OsteoporosisWeekly administration of teriparatide has been shown to reduce the risk of vertebral and non-vertebral fractures
in patients with osteoporosis at higher fracture risk in Japan. However, its efﬁcacy for hip fracture has not been
established. To gain insight into the effect of weekly teriparatide on the hip, hip structural analysis (HSA)
based on dual-energy X-ray absorptiometry (DXA) was performed using the data of 209 postmenopausal osteo-
porotic women who had participated in the original randomized, multicenter, double-blind, placebo-controlled
trial assessing the effects of once-weekly 56.5 μg teriparatide for 72 weeks. The DXA scans, obtained at baseline,
48 weeks and 72 weeks, were analyzed to extract bone mineral density (BMD) and cross-sectional geometrical
indices at the narrowest point on the neck (NN), the intertrochanteric region (IT), and the proximal shaft. Com-
pared with placebo after 72 weeks, the teriparatide group showed signiﬁcantly higher BMD, average cortical
thickness, bone cross-sectional area, and sectionmodulus, and lower buckling ratio at both the NN and IT regions.
No signiﬁcant expansion of periosteal diameter was observed at these regions. There were no signiﬁcant differ-
ences in BMD andHSA indices at the shaft region. The results indicate that overall structural strength in the prox-
imal femur increased compared to placebo, suggesting that once-weekly teriparatide effectively reverses changes
in hip geometry and strength with aging.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).Introduction
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. This is an open access article undermicroarchitecture through its anabolic effect on bone [1–5]. Once-
weekly teriparatide injection at a dose of 56.5 μg and daily teriparatide
injection at 20 μg are currently available for the treatment of primary
osteoporosis with high fracture risk in Japan. In both teriparatide treat-
ment regimens, marked reduction in fracture risk has been demonstrat-
ed at the spine, whereas their efﬁcacy has not been established for hip
fracture. Of the common osteoporotic fracture sites, hip fractures pres-
ent the greatest risk of morbidity and mortality, but hip fractures are
far less frequent than vertebral fractures, and most clinical trials are in-
sufﬁciently powered to show a comparable reduction in hip fractures.
The anti-fracture efﬁcacy of once-weekly 56.5 μg teriparatide
for 72 weeks was evaluated in 578 postmenopausal women and older
men with primary osteoporosis by a randomized, controlled trial,
the Teriparatide Once-Weekly Efﬁcacy Research (TOWER) trial [6].
Teriparatide administration increased BMD by 6.4%, 3.0%, and 2.3% at
the lumbar spine, total hip, and femoral neck, respectively, comparedthe CC BY license (http://creativecommons.org/licenses/by/3.0/).
Table 1
Baseline demographics and clinical characteristics of the teriparatide and placebo groups.
Teriparatide group
(n = 98)
Placebo group
(n = 111)
Age (years) 73.9 ± 5.4 74.1 ± 5.4
Body height (cm) 148.3 ± 5.4 147.7 ± 5.6
Body weight (kg) 51.0 ± 7.5 51.4 ± 7.8
Body mass index (BMI) (kg/m2) 23.2 ± 3.3 23.5 ± 3.1
Years after menopause (years) 24.4 ± 6.5 24.4 ± 6.6
Bone mineral density (T-score)
Lumbar spine (L2–4) −2.7 ± 1.0 −2.6 ± 1.0
Femoral neck −2.5 ± 0.8 −2.4 ± 0.8
Total hip −2.2 ± 1.0 −2.1 ± 0.9
Number of prevalent vertebral fractures 1.9 ± 1.4 1.7 ± 1.1
Data are mean ± SD.
Hip bone mineral densities are data at conventional DXA regions.
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tive risk reduction) compared to placebo. In addition to its antifracture
efﬁcacy at the spine, once-weekly treatment with teriparatide reduced
the risk of clinical fragility non-vertebral fractures by 67% compared to
placebo. Although the increase of hip BMD was signiﬁcant, the magni-
tude of the percent increase was less than half that of lumbar BMD.
The reduced risk of non-vertebral fracture may be partially due to the
changes in long bone geometry caused by teriparatide treatment.
Bone geometry refers to bone tissue distribution and alignment,
which are critical for both the structural and biomechanical properties
of bone [7]. In this context, the hip structural analysis (HSA) algorithm
was developed for noninvasive clinical evaluation of dual-energy
X-ray absorptiometry (DXA) of the proximal femur [8]. Prospective ep-
idemiological studies demonstrated the ability of thismethod to predict
hip fracture using indices of hip geometry. In a prospective case–control
study of 71 women and 25menmore than 60 years old [9], the femoral
neck diameter and section modulus (SM) were identiﬁed as indepen-
dent predictors of hip fracture risk after adjustment for BMD in both
women and men. Recent prospective studies of large epidemiologic
cohorts have shown that certain geometric properties, particularlyTable 2
Baseline HSA measurements and percent changes at 48 and 72 weeks.
Teriparatide group
(n = 98)
Site Parameter Baseline 48 weeks
Narrow neck BMD (g/cm2) 0.63 ± 0.10 2.4 ± 7.1a
CoTh (cm) 0.12 ± 0.02 2.8 ± 8.9a
CSA (cm2) 1.88 ± 0.29 1.9 ± 5.7a
OD (cm) 3.15 ± 0.22 −0. 3 ± 3.8
ED (cm) 2.92 ± 0.24 −0.5 ± 4.5
SM (cm3) 0.90 ± 0.16 1.3 ± 8.0
BR 15.89 ± 3.48 −2.6 ± 11.5
Intertrochanteric region BMD (g/cm2) 0.62 ± 0.12 2.3 ± 4.7a
CoTh (cm) 0.26 ± 0.05 1.8 ± 4.5a
CSA (cm2) 3.03 ± 0.56 1.6 ± 3.9a
OD (cm) 5.14 ± 0.30 −0.4 ± 2.2
ED (cm) 4.62 ± 0.33 −0.6 ± 2.5a
SM (cm3) 2.52 ± 0.59 0.9 ± 6.5
BR 12.20 ± 3.11 −2.2 ± 5.4a
Shaft BMD (g/cm2) 1.23 ± 0.21 0.1 ± 3.8
CoTh (cm) 0.45 ± 0.10 −0.1 ± 5.1
CSA (cm2) 3.19 ± 0.53 −0.1 ± 3.3
OD (cm) 2.74 ± 0.20 −0.0 ± 2.2
ED (cm) 1.84 ± 0.33 −0.0 ± 5.7
SM (cm3) 1.68 ± 0.32 −0.0 ± 4.6
BR 3.33 ± 0.97 −0.0 ± 7.2
Data are mean ± SD.
SM, section modulus; BR, buckling ratio; CSA, total mineralized bone area in cross-section; OD
a p b 0.05, compared with baseline.buckling ratio, cortical thickness, and outer diameter, predict incident
hip fracture aswell as conventional BMDat the proximal femur [10–12].
HSA is considered to be a suitable technique for geometrical assess-
ment. Although one must be cautious about the methodological limits
of measuring geometry from two-dimensional DXA scans, HSA could
provide critical insights into themechanisms of the therapeutic efﬁcacy
of anti-osteoporotic agents. The purpose of this studywas to investigate
the effect of once-weekly injection of 56.5 μg teriparatide on proximal
femoral geometry using HSA.
Subjects and methods
Subjects
The subjects in this analysis were a subgroup of the original TOWER
trial [6], and they included 209 ambulatory female patients with osteo-
porosis (N65 years old) enrolled at 25 sites equippedwith DXA systems
tomeasure hip BMD, bone geometry, andbiomechanical indices. The in-
clusion and exclusion criteria of the original TOWER trial were fulﬁlled
[6]. Subjects with 1 to 5 vertebral fractures with low BMD (T-score ≤
−1.67) were eligible. Subjects with diseases or using drugs affecting
bone or calciummetabolismwere excluded. The subjects were randomly
allocated to either weekly subcutaneous injection of 56.5 μg teriparatide
(teriparatide group) or placebo (placebo group) for 72 weeks. All subjects
received daily supplements of calcium (610mg), vitaminD3 (400 IU), and
magnesium (30 mg).
The original TOWER trialwas conducted in compliancewith the eth-
ical principles stated in the Declaration of Helsinki and Good Clinical
Practice. The trial was approved by the institutional review boards at
each site, and all subjects provided their written, informed consent be-
fore enrollment.
Methods
The subjects weremeasured for bone parameters byDXA at baseline
and after 48 and 72 weeks of treatment. All DXA devices were of the
Hologic system (Hologic Inc., Waltham, MA), and each machine wasPlacebo group
(n = 111)
72 weeks Baseline 48 weeks 72 weeks
3.4 ± 6.9a 0.63 ± 0.09 −0.7 ± 5.0 −0.5 ± 4.8
3.8 ± 8.2a 0.12 ± 0.02 −0.4 ± 6.3 0.1 ± 6.4
2.2 ± 5.6a 1.90 ± 0.27 −1.1 ± 4.4a −1.1 ± 4.3a
−1.1 ± 3.3a 3.16 ± 0.20 −0.4 ± 3.2 −0.6 ± 2.8a
−1.4 ± 4.0a 2.92 ± 0.21 −0.4 ± 3.7 −0.6 ± 3.3
2.6 ± 7.5a 0.90 ± 0.16 −0.2 ± 7.1 −0.8 ± 7.3
−4.5 ± 10.1a 15.77 ± 3.20 0.3 ± 8.3 −0.3 ± 8.1
3.1 ± 5.0a 0.63 ± 0.10 −0.8 ± 4.1a −1.4 ± 4.6a
2.1 ± 4.7a 0.27 ± 0.05 −1.0 ± 4.8 −0.9 ± 0.1a
2.6 ± 4.1a 3.10 ± 0.49 −0.6 ± 4.2 −0.9 ± 4.5
−0.3 ± 2.2 5.20 ± 0.28 0.3 ± 1.9 0.4 ± 2.1
−0.5 ± 2.6 4.67 ± 0.31 0.4 ± 2.1a 0.6 ± 2.4a
3.3 ± 7.4a 2.63 ± 0.60 0.9 ± 7.4 −0.0 ± 7.6
−2.3 ± 5.8a 11.88 ± 2.60 1.2 ± 5.7a 2.0 ± 5.9a
0.3 ± 3.8 1.24 ± 0.19 −0.3 ± 3.7 −0.5 ± 3.9
−0.2 ± 5.0 0.46 ± 0.09 0.5 ± 4.9 −0.8 ± 5.0
1.0 ± 3.6a 3.24 ± 0.47 0.0 ± 3.4 −0.1 ± 3.8
0.9 ± 1.7a 2.75 ± 0.19 −0.3 ± 2.0 0.4 ± 2.0a
1.6 ± 4.4a 1.83 ± 0.32 −0.8 ± 5.0 1.3 ± 5.2a
1.4 ± 5.1a 1.69 ± 0.26 −0.8 ± 4.9 1.0 ± 5.5
1.2 ± 6.9 3.25 ± 0.83 −0.8 ± 6.7 1.5 ± 7.0a
, outer diameter; ED, endocortical diameter; CoTh, cortical thickness.
Fig. 1. Mean ± standard error (SE) and percent changes from baseline in narrow neck
(NN, 1a), intertrochanteric region (IT, 1b), and shaft (1c) bone mineral density (BMD) at
48 weeks and 72 weeks of treatment with teriparatide and placebo. Solid and broken
lines correspond to teriparatide and placebo groups, respectively. To compare the differ-
ence between the two groups, the percent changes from baseline in hip structural analysis
(HSA) parameterswere analyzed using Student's t-test. *p b 0.05, comparedwith placebo.
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the reproducibility of themeasurementswithin±1.5% during the study
period. DXA scan data for the proximal femurwere analyzed usingAPEX
3.0 software (Hologic, Inc.), and all analyses were conducted by the
same technician (TT) in the Department of Radiological Technology,
Kawasaki College of Allied Health Professions.
The HSA algorithm is based on a principle ﬁrst articulated byMartin
and Burr [13], who demonstrated that mineral proﬁles created during
single photon absorptiometry are a projection of the corresponding
bone cross-section and can be used to deﬁne its geometry. As described
previously [8,14,15], the HSA algorithm derives the conventional BMD
(g/cm2), the outer diameter (OD, cm), the endocortical diameter (ED,
cm), the average cortical thickness (CoTh, cm), the total mineralized
bone area in the cross-section (CSA, cm2), the cross-sectional moment
of inertia (CSMI, cm4), and the section modulus (SM, cm3) directly
from the mass proﬁles. SM is computed as CSMI / dmax, where dmax
(cm) is the maximum distance between the center of the mass (cen-
troid) and the outer cortex. Another parameter, the buckling ratio
(BR), is estimated as the ratio of dmax to the estimated average CoTh de-
rived from an annulus model of the cross-section using the measured
OD, assuming that a ﬁxed proportion of CSA is in the cortex. CSA and
SM are indices of resistance to axial compressive and bending loads, re-
spectively, and BR is a crude index of susceptibility to local buckling
under bending loads.
The HSA software generates proﬁles of pixel values traversing the
proximal femur at three locations: the narrow neck (NN) across the
femoral neck at its narrowest point, the intertrochanteric region (IT)
along the angle bisector deﬁned by the neck and shaft axes, and across
the shaft at 30 mm below themost prominent portion of the lesser tro-
chanter. To avoid variation in the visualization of the lower border of the
lesser trochanter depending on the inner rotation of the hip joint, the
distance from the highest part of the lesser trochanter was made
constant to improve the reproducibility of bone shaft regions and to cor-
rectly determine the region of interest (ROI). At each of these locations,
ﬁve parallel proﬁles were generated, spaced one pixel apart, proximal
and distal to the three deﬁned locations. The ﬁve proﬁles were averaged
within each region, and the BMD, CSA, OD, ED, CoTh, SM, and BR were
reported.
Statistics
All statistical analyses were performed on subjects who had been
randomized and had evaluable observations for HSA assessment at
baseline and at 48 and 72 weeks. Paired and unpaired Student's t-tests
were used. All p values calculated in the analysis were two-sided and
were not adjusted for multiple testing. Statistical analyses were per-
formed with SAS version 9.1 (SAS Institute, Cary, NC, USA).
Results
Background characteristics
A total of 209 subjects were analyzed by the HSA program. There
were 98 subjects in the teriparatide group (mean age ± SD: 73.9 ±
5.4 years) and 111 subjects in the placebo group (74.1 ± 5.4 years).
Table 1 shows the subjects' background characteristics at baseline in
both groups. There were no signiﬁcant differences between the two
groups in age, height, weight, body mass index (BMI), years after men-
opause, BMD at the spine and hip, or the number of vertebral fractures
(p N 0.05).
Effect of teriparatide on BMD
Percentage changes in BMD of individual femoral regions frombase-
line are shown in Table 2. There were no signiﬁcant differences at base-
line for BMD at the NN, IT, and shaft between the teriparatide andplacebo groups. Compared to baseline, weekly teriparatide signiﬁcantly
increased BMD at the NN (2.4%, 48 weeks, p = 0.01; 3.4%, 72 weeks,
p b 0.01) and IT (2.3%, 48 weeks, p b 0.01; 3.1%, 72 weeks, p b 0.01).
No signiﬁcant increase was observed at the shaft (0.1%, 48 weeks,
p = 0.87; 0.3%, 72 weeks, p = 0.55).Effects of teriparatide on bone geometry parameters
Baseline and percent changes in bone geometry parameters are
shown in Table 2. There were no signiﬁcant differences at baseline for
any bone geometry parameter at the NN, IT, and shaft between the
teriparatide and placebo groups. Compared to baseline, weekly teri-
paratide signiﬁcantly increased: CoTh at the NN (2.8%, 48 weeks, p =
0.03; 3.8%, 72 weeks, p b 0.01) and IT (1.8%, 48 weeks, p b 0.01; 2.1%,
72 weeks, p = 0.01); CSA at the NN (1.9%, 48 weeks, p = 0.02; 2.2%,
72 weeks, p = 0.02), IT (1.6%, 48 weeks, p b 0.01; 2.6%, 72 weeks,
p b 0.01), and the shaft (1.0%, 72 weeks, p = 0.03); OD at the shaft
(0.9%, 72 weeks, p b 0.01); and ED at the shaft (1.6%, 72 weeks, p =
0.04). Teriparatide treatment also decreased OD at the NN (−1.1%,
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IT (−0.6%, 48 weeks, p = 0.02). In the placebo group, CoTh at the IT
(−0.9%, 72 weeks, p b 0.01), CSA at the NN (−1.1%, 48 weeks, p =
0.01;−1.1%, 72 weeks, p= 0.02), and OD at the NN (−0.6%, 72 weeks,
p = 0.04) decreased signiﬁcantly, whereas OD at the shaft (0.4%,
72 weeks, p = 0.04) and ED at the IT (0.4%, 48 weeks, p = 0.04; 0.6%,
72 weeks, p = 0.01) and shaft (1.3%, 72 weeks, p = 0.02) increased
signiﬁcantly.Effects of teriparatide on bone strength indices
Baseline and percent changes in bone strength indices are shown in
Table 2. There were no signiﬁcant differences at baseline for any bone
strength indices at the NN, IT, and shaft between the teriparatide and
placebo groups. Teriparatide treatment also decreased BR at the NN
(−4.5%, 72 weeks, p b 0.01) and IT (−2.2%, 48 weeks, p b 0.01;
−2.3%, 72 weeks, p b 0.01). In the placebo group, BR at the IT (1.2%,
48 weeks, p = 0.03; 2.0%, 72 weeks, p b 0.01) and shaft (1.5%,
72 weeks, p= 0.04) increased signiﬁcantly.Fig. 2.Mean ± SE and percent changes from baseline in cortical thickness (CoTh) in NN (1a),
IT (2b) and shaft (2c); outer diameter (OD) in NN (3a), IT (3b), and shaft (3c); and endocortica
with teriparatide and placebo. Solid and broken lines correspond to the teriparatide and place
changes from baseline in HSA parameters were analyzed using Student's t-test. *p b 0.05, comEffect of teriparatide on BMD compared to placebo
The comparison of BMD between the teriparatide and placebo
groups is shown in Fig. 1. No signiﬁcant differences in BMD were ob-
served at the shaft between the groups. Signiﬁcantly greater increases
in BMD were observed in the teriparatide group (48 and 72 weeks) at
the NN and IT (Figs. 1a and b).
Effects of teriparatide on bone geometry parameters compared to placebo
Comparisons of CoTh, CSA, OD, and ED between the two groups are
shown in Fig. 2. Signiﬁcantly greater increases in CoTh at the NN
(48 weeks, p b 0.01; 72 weeks, p b 0.01) and IT (48 weeks, p b 0.01;
72 weeks, p b 0.01) were observed in the teriparatide group (Figs. 2—
1a and b). There was no signiﬁcant difference in CoTh at the shaft
(Fig. 2—1c). Signiﬁcantly greater increases in CSA values were observed
at the NN (48 weeks, p b 0.01; 72 weeks, p b 0.01) and IT (48 weeks,
p b 0.01; 72 weeks, p b 0.01) in the teriparatide group (Figs. 2—2a
and b). There was no signiﬁcant difference in CSA at the shaft (Fig. 2
—2c). A signiﬁcantly greater decrease in OD was observed at the ITIT (1b), and shaft (1c); total mineralized bone area in the cross-section (CSA) in NN (2a),
l diameter (ED) in NN (4a), IT (4b), and shaft (4c) at 48 weeks and 72 weeks of treatment
bo groups, respectively. To compare the difference between the two groups, the percent
pared with placebo.
Fig. 2 (continued).
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(Fig. 2—3b). There were no signiﬁcant differences in OD at the NN
and shaft (Figs. 2—3a and c). A signiﬁcantly greater decrease in ED
at the IT (48 weeks, p b 0.01; 72 weeks, p b 0.01) was observed in
the teriparatide group (Fig. 2—4b). There were no signiﬁcant differ-
ences in ED at the NN and shaft (Figs. 2—4a and c). In summary,
both CoTh and CSA increased in the NN and IT regions following treat-
ment with teriparatide; both OD and ED decreased in IT regions fol-
lowing treatment with teriparatide compared to placebo.Effects of teriparatide on bone strength indices compared to placebo
Percent changes in bone strength indices are shown in Fig. 3. SM
showed signiﬁcantly greater increases compared to placebo in the
teriparatide group at the NN (72 weeks, p b 0.01) and IT (72 weeks,
p b 0.01) (Figs. 3—2a and b). There was no signiﬁcant difference in
SM at the shaft (Fig. 3—2c). BR values showed signiﬁcantly greater de-
creases in the teriparatide group at the NN (48 weeks, p = 0.04;
72 weeks, p b 0.01) and IT (48 weeks, p b 0.01; 72 weeks, p b 0.01)
compared to placebo (Figs. 3—3a and b). There was no signiﬁcant dif-
ference in BR at the shaft (Fig. 3—3c).Discussion
This subgroup study using HSA demonstrated the changes of BMD,
bone geometry, and mechanical properties at the proximal femur with
once-weekly injection of 56.5 μg teriparatide for 72 weeks. This is the
ﬁrst longitudinal HSA study of weekly teriparatide including compari-
son with a placebo group. Previous studies have evaluated the effects
of daily teriparatide on hip geometry and its biomechanical properties
using HSA [16]. The effects of once-weekly teriparatide injection on
hip geometry in this study are roughly similar to the results with daily
teriparatide injection.
In this study, CoTh and CSA increased, while OD and ED remained
unchanged or decreased at the NN and IT over 72 weeks of once-
weekly teriparatide treatment. The results suggest that bone formation
took place at the endosteal and trabecular bone surfaces and not at the
periosteal surface. Previous reports suggested that daily treatment with
teriparatide stimulates new bone formation on both the periosteal and
endosteal surfaces [5,17]. The difference may be explained by the dose
of teriparatide or the timing of injection (daily versus weekly). General-
ly, the diameter of bone expands with age to compensate for the de-
crease in bone strength due to age-related bone loss [18–21].
Once-weekly teriparatide treatment increased CoTh without an
Fig. 3.Mean ± SE and percent changes from baseline in section modulus (SM) in NN (1a), IT (1b), and shaft (1c), and buckling ratio (BR) in NN (2a), IT (2b), and shaft (2c) at 48 and
72 weeks of treatment with teriparatide and placebo. Solid and broken lines correspond to teriparatide and placebo groups, respectively. To compare the difference between the two
groups, the percent changes from baseline in HSA parameters were analyzed using Student's t-test. *p b 0.05, compared with placebo.
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indicate anti-aging effects of teriparatide treatment. Reﬂecting the in-
crease in CoTh, a signiﬁcant decrease in BR was also observed in the
teriparatide group.
Contrary to our expectations, OD at the NN showed a small but sig-
niﬁcant decrease compared with baseline in the placebo group, al-
though it showed an increase both at the IT and shaft. The decrease in
OD at the NN in the placebo group is not consistent with previous re-
ports that showed a signiﬁcant age-related increase in OD by HSA [20,
22]. At a region of very thin cortex, such as the upper border of the fem-
oral neck, the edge detection error inDXA analysis due to thepartial vol-
ume effect may become evident, resulting in the apparent decrease in
OD. Such an error in edge detection would be exaggerated by the in-
crease in cortical porosity and the decrease in mineralization density
of bone tissue. In this context, the decreased tendency in OD in the
teriparatide group compared with the placebo group at the NN and IT
may be an artifact of edge detection error.
In contrast to the changes at the NN and IT with teriparatide treat-
ment, no signiﬁcant differences were observed at the shaft in HSA indi-
ces between the teriparatide and placebo groups. Similar results have
been reported in a study with daily teriparatide injection [22].The present HSA study results are consistent with the three-
dimensional assessment of proximal femoral geometry by quantitative
computed tomography (QCT) using a small sample of the TOWER trial
[23]. The present study conﬁrmed the results of the QCT study using a
larger sample from the same trial. Taken together with the results of
the QCT study, once-weekly teriparatide injection appears to reverse
age-related deteriorations in bone structural strength by increasing
CoTh, CSA, and BMD, while not increasing cortical perimeter at the NN
and IT. Thus, once-weekly injection of 56.5 μg teriparatide may have
the potential to reduce the risk of hip fracture.
The present study has some limitations based on themethodological
assumptions in HSA. First, since HSA assumes a ﬁxed proportion of cor-
tical and cancellous bonemass to calculate ED, the estimate of ED and its
derived measurements such as CoTh and BR are inﬂuenced when bone
mass changes in cortical and cancellous bone are not proportional. It has
been suggested that the increased bone mass with daily teriparatide
treatment predominantly involves cancellous bone [24,25]. However,
the QCT study using a small sample of the TOWER trial also showed a
signiﬁcant increase in CoTh, as well as in CSA [23]. Thus, we think that
the differential effect on bone mass between cortical and cancellous
bone would be small with weekly teriparatide treatment.
81T. Sone et al. / Bone 64 (2014) 75–81Another limitation is the possible error due to the assumption of
ﬁxed bone mineralization density in HSA. Given that teriparatide
tends to decrease the mean mineralization density of bone tissue,
the increases in CSA, CoTh, and SM with treatments would be
underestimated.
In conclusion, HSA showed that once-weekly teriparatide increased
CoTh and CSA and improved biomechanical indices. Moreover, once-
weekly teriparatide did not increase OD and ED, but seemed to effec-
tively reverse changes in hip geometry and strength with aging. Taken
together with its anti-fracture efﬁcacy in the spine [6], once-weekly
56.5 μg teriparatide administration is an option for the prevention of
spinal fractures and may have the potential to prevent hip fractures.
Disclosure
This study was jointly designed by all authors and the sponsor
(Asahi Kasei Pharma Corporation). Funding for this study was provided
by Asahi Kasei Pharma Corporation. The sponsor of the study participat-
ed in the study design, data analysis, and writing of the report, and had
responsibility for quality control. The corresponding author had full ac-
cess to all the data in the study andﬁnal responsibility for the decision to
submit the manuscript for publication.
TSo has received research grants and consulting fees from Astellas
Pharma, Daiichi-Sankyo, Pﬁzer, and Takeda Pharmaceutical. MI has re-
ceived research grants and consulting fees or other remuneration from
Chugai Pharmaceutical, Daiichi Sankyo, Ono Pharmaceutical, and Asahi
Kasei Pharma. MF has received consulting fees from Astellas Pharma
and Asahi Kasei Pharma. TT has nothing to disclose. TSu has received re-
search grants and consulting fees from Asahi Kasei Pharma and Daiichi
Sankyo. MS has received consulting fees from Asahi Kasei Pharma,
Daiichi Sankyo, Chugai Pharmaceutical, and Teijin Pharma. TY is an em-
ployee of Asahi Kasei Pharma. TN has received research grants and/or
consulting fees from Chugai Pharmaceutical, Teijin Pharma, Asahi
Kasei Pharma, and Daiichi Sankyo. TN is a counselor for hospital admin-
istration and socialmedical insurancewith the JapanMinistry of Health,
Labour and Welfare.
Acknowledgments
The authors would like to thank the doctors who participated in
the clinical trial. English editing was performed by FORTE Science
Communications.
References
[1] Miyauchi A, Matsumoto T, Sugimoto T, Tsujimoto M, Warner MR, Nakamura T. Ef-
fects of teriparatide on bone mineral density and bone turnover markers in
Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical
study: 12-month, randomized, placebo-controlled, double-blind and 12-month
open-label phases. Bone 2010;47:493–502.
[2] Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, et al. Effects
of daily treatment with parathyroid hormone on bone microarchitecture and
turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner
Res 2001;16:1846–53.
[3] Hodsman AB, Kisiel M, Adachi JD, Fraher LJ, Watson PH. Histomorphometric evi-
dence for increased bone turnover and cortical thickness without increased corticalporosity after 2 years of cyclical hPTH (1–34) therapy in women with severe osteo-
porosis. Bone 2000;27:311–8.
[4] Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF. Recombinant human
parathyroid hormone (1–34) [teriparatide] improves both cortical and cancellous
bone structure. J Bone Miner Res 2003;18:1932–41.
[5] Zanchetta JR, Bogado CE, Ferretti JL, Wang O, Wilson MG, Sato M, et al. Effects of
teriparatide [recombinant human parathyroid hormone (1–34)] on cortical bone
in postmenopausal women with osteoporosis. J Bone Miner Res 2003;18:539–43.
[6] Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Random-
ized teriparatide [human parathyroid hormone (PTH) 1–34] Once-Weekly Efﬁcacy
Research (TOWER) trial for examining the reduction in new vertebral fractures in
subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab
2012;97:3097–106.
[7] Yoshikawa T, Turner CH, Peacock M, Slemenda CW, Weaver CM, Teegarden D, et al.
Geometric structure of the femoral neck measured using dual-energy X-ray absorp-
tiometry. J Bone Miner Res 1994;9:1053–64.
[8] Beck TJ, Ruff CB, Warden KE, Scott Jr WW, Rao GU. Predicting femoral neck strength
from bone mineral data. A structural approach. Invest Radiol 1990;25:6–18.
[9] Ahlborg HG, Nguyen ND, Nguyen TV, Center JR, Eisman JA. Contribution of hip
strength indices to hip fracture risk in elderly men and women. J Bone Miner Res
2005;20:1820–7.
[10] Rivadeneira F, Zillikens MC, De Laet CE, Hofman A, Uitterlinden AG, Beck TJ, et al.
Femoral neck BMD is a strong predictor of hip fracture susceptibility in elderly
men and women because it detects cortical bone instability: the Rotterdam Study.
J Bone Miner Res 2007;22:1781–90.
[11] Kaptoge S, Beck TJ, Reeve J, Stone KL, Hillier TA, Cauley JA, et al. Prediction of incident
hip fracture risk by femur geometry variables measured by hip structural analysis in
the study of osteoporotic fractures. J Bone Miner Res 2008;23:1892–904.
[12] LaCroix AZ, Beck TJ, Cauley JA, Lewis CE, Bassford T, Jackson R, et al. Hip structural
geometry and incidence of hip fracture in postmenopausal women: what does it
add to conventional bone mineral density? Osteoporos Int 2010;21:919–29.
[13] Martin RB, Burr DB. Non-invasive measurement of long bone cross-sectional
moment of inertia by photon absorptiometry. J Biomech 1984;17:195–201.
[14] Beck TJ. Extending DXA, beyond bone mineral density: understanding hip structure
analysis. Curr Osteoporos Rep 2007;5:49–55.
[15] Beck T. Measuring the structural strength of bones with dual-energy X-ray absorpti-
ometry: principles, technical limitations, and future possibilities. Osteoporos Int
2003;14:S81–8.
[16] Uusi-Rasi Kirsti, Semanick Lisa M, Zanchetta Jose R, Bogado Cesar E, Eriksen Erik
F, Sato Masahiko, et al. Effects of teriparatide [rhPTH (1–34)] treatment on
structural geometry of the proximal femur in elderly osteoporotic women.
Bone 2005;36:948–58.
[17] Lindsay R, Zhou H, Cosman F, Nieves J, Dempster DW, Hodsman AB. Effects of a one-
month treatment with PTH(1–34) on bone formation on cancellous, endocortical,
and periosteal surfaces of the human ilium. J Bone Miner Res 2007;22:495–502.
[18] Seeman E. Pathogenesis of bone fragility in women and men. Lancet
2002;359:1841–50.
[19] Seeman E. Periosteal bone formation—a neglected determinant of bone strength. N
Engl J Med 2003;349:320–3.
[20] Beck TJ, Oreskovic TL, Stone KL, Ruff CB, Ensrud K, Nevitt MC, et al. Structural adap-
tation to changing skeletal load in the progression toward hip fragility: the study of
osteoporotic fractures. J Bone Miner Res 2001;16:1108–19.
[21] Feik SA, Thomas CD, Bruns R, Clement JG. Regional variations in corticalmodeling in the
femoral mid-shaft: sex and age differences. Am J Phys Anthropol 2000;112:191–205.
[22] Uusi-Rasia K, Semanicka LM, Zanchettab JR, Bogado CE, Eriksenc EF, Sato M, et al. Ef-
fects of teriparatide [rhPTH (1–34)] treatment on structural geometry of the proxi-
mal femur in elderly osteoporotic women. Bone 2005;36:948–58.
[23] Ito M, Oishi R, Fukunaga M, Sone T, Sugimoto T, Shiraki M, et al. The effects of once-
weekly teriparatide on hip structure and biomechanical properties assessed by CT.
Osteoporos Int 2014;25:1163–72.
[24] Sato M, Westmore M, Ma YL, Schmidt A, Zeng QQ, Glass EV, et al. Teriparatide
[PTH(1–34)] strengthens the proximal femur of ovariectomized nonhuman
primates despite increasing porosity. J Bone Miner Res 2004;19:623–9.
[25] Keaveny TM, McClung MR, Wan X, Kopperdahl DL, Mitlak BH, Krohn K. Femoral
strength in osteoporotic women treated with teriparatide or alendronate. Bone
2012;50:165–70.
